Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.

Okayama N, Nishioka M, Hazama S, Sakai K, Suehiro Y, Maekawa M, Sakamoto J, Iwamoto S, Kato T, Mishima H, Oka M, Hinoda Y.

Jpn J Clin Oncol. 2011 Feb;41(2):165-71. doi: 10.1093/jjco/hyq173. Epub 2010 Oct 5.

PMID:
20926413
2.

Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.

Lamy A, Blanchard F, Le Pessot F, Sesboüé R, Di Fiore F, Bossut J, Fiant E, Frébourg T, Sabourin JC.

Mod Pathol. 2011 Aug;24(8):1090-100. doi: 10.1038/modpathol.2011.60. Epub 2011 Apr 22.

3.

KRas and BRaf mutational status analysis from formalin-fixed, paraffin-embedded tissues using multiplex polymerase chain reaction-based assay.

Jakubauskas A, Griskevicius L.

Arch Pathol Lab Med. 2010 Apr;134(4):620-4. doi: 10.1043/1543-2165-134.4.620.

PMID:
20367313
4.

Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.

Ausch C, Buxhofer-Ausch V, Oberkanins C, Holzer B, Minai-Pour M, Jahn S, Dandachi N, Zeillinger R, Kriegshäuser G.

J Mol Diagn. 2009 Nov;11(6):508-13. doi: 10.2353/jmoldx.2009.090022. Epub 2009 Oct 1.

5.

Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay.

Chang YS, Er TK, Lu HC, Yeh KT, Chang JG.

Clin Chim Acta. 2014 Sep 25;436:169-75. doi: 10.1016/j.cca.2014.05.008. Epub 2014 May 24.

PMID:
24863805
6.

Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.

Lee S, Brophy VH, Cao J, Velez M, Hoeppner C, Soviero S, Lawrence HJ.

Virchows Arch. 2012 Feb;460(2):141-9. doi: 10.1007/s00428-011-1180-0. Epub 2011 Dec 16.

7.
8.

Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing.

Bando H, Tsuchihara K, Yoshino T, Kojima M, Ogasawara N, Fukushima H, Ochiai A, Ohtsu A, Esumi H.

Jpn J Clin Oncol. 2011 Feb;41(2):239-44. doi: 10.1093/jjco/hyq216. Epub 2010 Nov 26.

PMID:
21113056
9.

Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers.

Ogasawara N, Bando H, Kawamoto Y, Yoshino T, Tsuchihara K, Ohtsu A, Esumi H.

Jpn J Clin Oncol. 2011 Jan;41(1):52-6. doi: 10.1093/jjco/hyq151. Epub 2010 Aug 9.

PMID:
20696815
10.
11.

KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues.

Solassol J, Ramos J, Crapez E, Saifi M, Mangé A, Vianès E, Lamy PJ, Costes V, Maudelonde T.

Int J Mol Sci. 2011;12(5):3191-204. doi: 10.3390/ijms12053191. Epub 2011 May 17.

12.

A comparability study of 5 commercial KRAS tests.

Oliner K, Juan T, Suggs S, Wolf M, Sarosi I, Freeman DJ, Gyuris T, Baron W, Bakker A, Parker A, Patterson SD.

Diagn Pathol. 2010 Apr 16;5:23. doi: 10.1186/1746-1596-5-23.

13.

High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples.

De Miglio MR, Mura A, Uras MG, Manca A, Contini M, Murgia L, Zinellu A, Sotgia S, Carru C, Massarelli G, Cossu-Rocca P.

Diagn Mol Pathol. 2010 Dec;19(4):201-8. doi: 10.1097/PDM.0b013e3181db67d5.

PMID:
21052001
14.

Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.

Laosinchai-Wolf W, Ye F, Tran V, Yang Z, White R, Bloom K, Choppa P, Labourier E.

J Clin Pathol. 2011 Jan;64(1):30-6. doi: 10.1136/jcp.2010.081539. Epub 2010 Oct 28.

PMID:
21030527
15.

Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas.

Harlé A, Busser B, Rouyer M, Harter V, Genin P, Leroux A, Merlin JL.

Virchows Arch. 2013 Mar;462(3):329-35. doi: 10.1007/s00428-013-1380-x. Epub 2013 Feb 12.

PMID:
23400679
16.

Applicability of a System for fully automated nucleic acid extraction from formalin-fixed paraffin-embedded sections for routine KRAS mutation testing.

Lehmann A, Schewe C, Hennig G, Denkert C, Weichert W, Budczies J, Dietel M.

Diagn Mol Pathol. 2012 Jun;21(2):114-9. doi: 10.1097/PDM.0b013e31823569ca.

PMID:
22555094
17.

Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.

Feigelson HS, Goddard KA, Johnson MA, Funk KC, Rahm AK, Kauffman TL, Chitale DA, Le Marchand L, Richards CS.

BMC Res Notes. 2012 Apr 25;5:196. doi: 10.1186/1756-0500-5-196.

18.

Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.

Perez K, Walsh R, Brilliant K, Noble L, Yakirevich E, Breese V, Jackson C, Chatterjee D, Pricolo V, Roth L, Shah N, Cataldo T, Safran H, Hixson D, Quesenberry P.

Exp Mol Pathol. 2013 Aug;95(1):74-82. doi: 10.1016/j.yexmp.2013.01.004. Epub 2013 Mar 22.

19.

KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.

Lewandowska MA, Jóźwicki W, Żurawski B.

Mol Diagn Ther. 2013 Jun;17(3):193-203. doi: 10.1007/s40291-013-0025-8.

20.

KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.

Sundström M, Edlund K, Lindell M, Glimelius B, Birgisson H, Micke P, Botling J.

BMC Cancer. 2010 Dec 1;10:660. doi: 10.1186/1471-2407-10-660.

Supplemental Content

Support Center